On this episode of Managed Care Cast, we speak with one of the authors of a paper published this month in Health Affairs about the utilization of substance use disorder treatment (SUD) services between 2010 and 2019, and why more needs to be done to get more individuals into treatment.
Drug overdose deaths are skyrocketing, with more than 100,000 people dying in 2021, according to the CDC. Obtaining treatment for substance use disorders (SUDs) has never been easy, and this month in Health Affairs, a paper examined trends in the use of treatment services to see what, if anything, changed from 2010 to 2019.
Despite an increase in insurance coverage over much of that time period and other policy changes, the results were disappointing, according to one of the authors interviewed about the findings on today’s Managed Care Cast. Brendan Saloner, PhD, is an associate professor at the Johns Hopkins Bloomberg School of Public Health who specializes in health policy, particularly policies that affect vulnerable populations, including those with SUDs and behavioral or mental health issues.
Listen above or through one of these podcast services:
FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD
January 28th 2025The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen